SR-016 is under clinical development by Suzhou Ribo Life Sciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect SR-016’s likelihood of approval (LoA) and phase transition for Hepatitis B took place on 27 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SR-016 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
SR-016 is under development for the treatment of Hepatitis B. The drug candidate is a siRNA (small interference RNA). The drug candidate is administered by subcutaneous route. It is delivered using RBP131 which is a liposomal nanoparticle for liver-targeted systemic delivery of siRNA.
Suzhou Ribo Life Sciences overview
Suzhou Ribo Life Sciences (Ribo) is a drug development company that develops nucleic acid drugs and related products based on the RNA interference (RNAi) technology. The company’s pipeline products include QPI-1007, RB-RQ007, RB-T2D003, RB-PCA006, RB-AG010 and others. Ribo also develops RBP131, a lipid nanoparticle based and liver-targeted delivery system for systemic delivery siRNA drug. The company’s RNAi platform develops biomedicine and is capable of “silencing” genes specifically using RNAi. Ribo is headquartered in Kunshan, Jiangsu, China.
Quick View SR-016 LOA Data
|Highest Development Stage|